Meitheal Pharmaceuticals announces FDA approval of Enoxaparin Sodium Injection, USP

This article was originally published here

Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder. Enoxaparin had annual sales of approximately $616M in

The post Meitheal Pharmaceuticals announces FDA approval of Enoxaparin Sodium Injection, USP appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply